Todd A. Trapp - 04 Apr 2022 Form 4 Insider Report for ABIOMED INC

Role
VICE PRESIDENT, CFO
Signature
/s/ Marc A. Began (by power of attorney)
Issuer symbol
N/A
Transactions as of
04 Apr 2022
Net transactions value
-$333,000
Form type
4
Filing time
06 Apr 2022, 16:26:18 UTC
Previous filing
07 Jan 2022
Next filing
27 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NASD Common Stock, $0.01 par value Sale $333,000 -1,000 -7.1% $333.00* 13,063 04 Apr 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NASD Stock Option (Right to Buy) 7,000 04 Apr 2022 Common Stock 0 $266.39 Direct F3, F4
holding NASD Stock Option (Right to Buy) 6,530 04 Apr 2022 Common Stock 0 $223.90 Direct F3, F4
holding NASD Stock Option (Right to Buy) 3,737 04 Apr 2022 Common Stock 0 $283.88 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of common stock pursuant to reporting owner's 10b5-1 plan.
F2 This price represents the sale price of the transactions on the reported date at $333.00. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
F3 Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
F4 These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.